10 hours ago
Novo Exits Hims & Hers Partnership, Citing Compounding Concerns
Novo Nordisk A/S is terminating a recently formed obesity-drug partnership with Hims & Hers Health Inc. that had been touted as a way to boost sales in the US.
The Danish drugmaker cited concerns about sales of compounded drugs and misleading marketing in a statement Monday. Hims & Hers shares plunged 18% in trading before US exchanges opened. Novo fell as much as 5% in Copenhagen.
